November 12, 2022 – Therapy with DNA repair inhibitors in early phase clinical trials

Current guidelines recommend against the routine use of rFVIIa alone for the reversal of VKAs (30)

November 12, 2022 climat2050

Current guidelines recommend against the routine use of rFVIIa alone for the reversal of VKAs (30). situations. Administer triggered PCC (50 U/kg) or 4-element PCC

Day: November 12, 2022

﻿Current guidelines recommend against the routine use of rFVIIa alone for the reversal of VKAs (30)

Current guidelines recommend against the routine use of rFVIIa alone for the reversal of VKAs (30)